A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Latest Information Update: 27 Mar 2025
At a glance
- Drugs HD-P023 (Primary) ; Empagliflozin; Teneligliptin
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Handok Inc
- 25 Mar 2025 New trial record